GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Debt-to-EBITDA

Joinn Laboratories (China) Co (HKSE:06127) Debt-to-EBITDA : 0.27 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Joinn Laboratories (China) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was HK$34 Mil. Joinn Laboratories (China) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was HK$23 Mil. Joinn Laboratories (China) Co's annualized EBITDA for the quarter that ended in Mar. 2025 was HK$214 Mil. Joinn Laboratories (China) Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 0.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Joinn Laboratories (China) Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:06127' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06   Med: 0.12   Max: 0.26
Current: 0.12

During the past 13 years, the highest Debt-to-EBITDA Ratio of Joinn Laboratories (China) Co was 0.26. The lowest was 0.06. And the median was 0.12.

HKSE:06127's Debt-to-EBITDA is ranked better than
89.72% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.68 vs HKSE:06127: 0.12

Joinn Laboratories (China) Co Debt-to-EBITDA Historical Data

The historical data trend for Joinn Laboratories (China) Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Debt-to-EBITDA Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.13 0.06 0.11 0.26

Joinn Laboratories (China) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 0.12 0.16 0.09 0.27

Competitive Comparison of Joinn Laboratories (China) Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Debt-to-EBITDA falls into.


;
;

Joinn Laboratories (China) Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Joinn Laboratories (China) Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(42.039 + 23.062) / 250.219
=0.26

Joinn Laboratories (China) Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(34.44 + 22.513) / 214.036
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Joinn Laboratories (China) Co  (HKSE:06127) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Joinn Laboratories (China) Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Ubs Group Ag 2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities 2102 Investment manager
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Apg Asset Management N.v. 2101 Beneficial owner
Apg Groep N.v. 2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines